Skip to main content

Featured

10 Proven Ways Canadian Families Can Save Big on Groceries This Summer

  Published on moneysavings.ca | Personal Finance & Everyday Savings If you've been to a Canadian grocery store lately, you already know — the sticker shock is real. Feeding a family in Canada has become one of the biggest household expenses, and with food prices still elevated, many families are looking for smart, practical ways to stretch every dollar. The good news? You don't have to sacrifice quality or go hungry to save big. With a few simple habit changes, many Canadian families are cutting hundreds of dollars off their monthly grocery bills. Here are 10 strategies you can start using today. 1. Shop the "Reduced for Quick Sale" Section First Every major grocery store in Canada — from Loblaws to Sobeys to Walmart — has a section dedicated to items nearing their best-before date. These items are often marked down by 30–50%, and they're perfectly good to eat within a day or two (or freeze immediately). Make it a habit to check this section the moment...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment